During institutional inquiries, Guilin Sanjin Pharmaceuticals (002275) stated that currently, their front-line products, including the watermelon frost series and sanjin tablets series, account for nearly 80% of the sales revenue. The company is currently undergoing secondary product development initiatives, such as launching new formulations, increasing indications, and combinations with other drugs. The company's products still have potential to increase sales in the corresponding markets for oral, throat, urinary systems, with a great proportion of OTC products. The next step is to expand sales in hospital channels.